Immuneering’s (IMRX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Immuneering (NASDAQ:IMRX) in a report published on Thursday morning,Benzinga reports. They currently have a $20.00 price objective on the stock.

IMRX has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Tuesday, September 30th. Oppenheimer increased their price target on shares of Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immuneering in a research report on Wednesday, October 8th. Leerink Partners started coverage on shares of Immuneering in a research note on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Mizuho set a $12.00 target price on shares of Immuneering in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Stock Down 1.6%

Shares of IMRX stock opened at $6.35 on Thursday. The firm has a market cap of $263.97 million, a price-to-earnings ratio of -3.57 and a beta of 0.46. The company’s 50 day moving average is $6.86 and its 200 day moving average is $4.41. Immuneering has a 52-week low of $1.10 and a 52-week high of $10.08.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Analysts anticipate that Immuneering will post -1.86 EPS for the current fiscal year.

Insider Activity

In related news, Director Peter Feinberg acquired 7,500 shares of the stock in a transaction dated Friday, October 3rd. The stock was acquired at an average cost of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the purchase, the director owned 156,766 shares of the company’s stock, valued at approximately $1,045,629.22. This represents a 5.02% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired a total of 20,800 shares of company stock valued at $143,754 over the last three months. Company insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Immuneering

Several hedge funds have recently made changes to their positions in IMRX. Geode Capital Management LLC lifted its position in Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after acquiring an additional 4,458 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Immuneering in the third quarter worth about $35,000. Future Financial Wealth Managment LLC acquired a new stake in shares of Immuneering during the third quarter worth about $35,000. Dimensional Fund Advisors LP lifted its holdings in shares of Immuneering by 46.4% during the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after purchasing an additional 6,196 shares during the period. Finally, HighTower Advisors LLC boosted its position in Immuneering by 17.7% in the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock valued at $128,000 after buying an additional 12,600 shares during the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.